Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11554110 | 0.92 | CYP2A6 (0.44) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL20282452 | 0.92 | PGR (0.47) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL20282639 | 0.92 | PGR (0.47) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL16558189 | 0.90 | KDM4E (0.53) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL15240406 | 0.88 | KCNH2 (0.46) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL21475116 | 0.88 | RAB9A (0.56) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL18010706 | 0.88 | CYP2A6 (0.42) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL16906004 | 0.88 | ALDH1A1 (0.48) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL29669698 | 0.88 | KCNH2 (0.46) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL13564574 | 0.87 | CYP2A6 (0.44) | CYP2A6NOS3NOS1NOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| CN-1829509-A | Pharmaceutical composition for treating tumors | COMBINATORX INC (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| WO-2004002430-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
| EP-1105381-A1 | DICATIONIC DIBENZOFURAN AND DIBENZOTHIOPHENE COMPOUNDS AND METHODS OF USE THEREOF | The University of North Carolina at Chapel Hill (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6172104-B1 | ADMINISTERING TO TREAT PNEUMOCYSTIS CARINII PNEUMONIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-01-09 | — | — | US | disclosed |
| WO-2000010990-A2 | DICATIONIC DIBENZOFURAN AND DIBENZOTHIOPHENE COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | CYP2A6 261/4885NOS3 3755/4885NOS1 4202/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | CYP2A6 813/4885NOS3 2525/4885NOS1 3187/4885 |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | CYP2A6 3536/4885NOS3 3000/4885NOS1 3420/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | CYP2A6 2597/4885NOS3 1463/4885NOS1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.